- Home
- AORT vs AUPH Comparison
AORT vs AUPH Comparison
Compare AORT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- AUPH
- Stock Information
- Founded
- AORT 1984
- AUPH 1993
- Country
- AORT United States
- AUPH Canada
- Employees
- AORT N/A
- AUPH N/A
- Industry
- AORT Medical/Dental Instruments
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- AUPH Health Care
- Exchange
- AORT Nasdaq
- AUPH Nasdaq
- Market Cap
- AORT 1.1B
- AUPH 1.0B
- IPO Year
- AORT 1993
- AUPH 1999
- Fundamental
- Price
- AORT $26.65
- AUPH $8.12
- Analyst Decision
- AORT Strong Buy
- AUPH Strong Buy
- Analyst Count
- AORT 5
- AUPH 3
- Target Price
- AORT $31.00
- AUPH $10.33
- AVG Volume (30 Days)
- AORT 224.5K
- AUPH 1.3M
- Earning Date
- AORT 11-07-2024
- AUPH 11-07-2024
- Dividend Yield
- AORT N/A
- AUPH N/A
- EPS Growth
- AORT N/A
- AUPH N/A
- EPS
- AORT N/A
- AUPH N/A
- Revenue
- AORT $384,899,000.00
- AUPH $220,361,000.00
- Revenue This Year
- AORT $12.93
- AUPH $36.52
- Revenue Next Year
- AORT $9.89
- AUPH $19.02
- P/E Ratio
- AORT N/A
- AUPH N/A
- Revenue Growth
- AORT 13.29
- AUPH 38.72
- 52 Week Low
- AORT $13.42
- AUPH $4.71
- 52 Week High
- AORT $30.00
- AUPH $10.05
- Technical
- Relative Strength Index (RSI)
- AORT 45.57
- AUPH 62.64
- Support Level
- AORT $27.11
- AUPH $8.06
- Resistance Level
- AORT $30.00
- AUPH $8.70
- Average True Range (ATR)
- AORT 1.05
- AUPH 0.34
- MACD
- AORT -0.14
- AUPH 0.07
- Stochastic Oscillator
- AORT 16.25
- AUPH 63.74
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.